Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Aequus Pharmaceuticals Inc V.AQS

Alternate Symbol(s):  AQSZF

Aequus Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company focused on developing, advancing, and promoting differentiated products. The Company is engaged in the sale and marketing of several commercial products in ophthalmology and transplant. Its pipeline products include Evolve Intensive Gel, Evolve Daily Intensive, SCOPE Portfolio, Zimed PF and REV-0100 / ReVision. Evolve Intensive Gel and Evolve Daily Intensive contains lubricating eye drops intended for use in the relief of discomfort that arises from dry eye sensations, including dryness, soreness, feelings of grit, and irritation. Zimed PF is a preservative-free multi-dose Bimatoprost for glaucoma patients in Canada. REV-0100 is in preclinical development as a treatment for Stargardt disease. It plans to build on its Canadian commercial platform through the launch of additional products that are either created internally or brought in through an acquisition or license.


TSXV:AQS - Post by User

Post by ShortOnCashon Jun 30, 2024 5:39pm
74 Views
Post# 36112828

"ZIMED(TM) PF sales are continuing to accelerate" May 22, NR

"ZIMED(TM) PF sales are continuing to accelerate" May 22, NRNext set of numbers are due soon....

The MacD is showing the next level up is upon us.......

This is where a Company cant over promote, and the market needs to speculate, and figure it out on their own.

With the PAUL(TM) device around the corner.....This should be a $10m market cap.....we sit at $2.6

So this goes $0.08 to $0.10 real quick.....

This is a "Golden Goose", a company about to turn a corner after big $$$ being spent to get there.

Back to the old days.....real value with a real story




<< Previous
Bullboard Posts
Next >>